The Use of Biologic Therapy in the pregnant patient

Practical Gastroenterology

Volumn 34, Issue 9, 2010, Pages 33-36

  Mahadevan, Uma ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CERTOLIZUMAB PEGOL; ETANERCEPT; IMMUNOGLOBULIN; INFLIXIMAB; MEASLES MUMPS RUBELLA VACCINE; MERCAPTOPURINE; PNEUMOCOCCUS VACCINE; POLIOMYELITIS VACCINE; ROTAVIRUS VACCINE; TUMOR NECROSIS FACTOR INHIBITOR;

ANTIBODY TITER; ANUS ATRESIA; ARTICLE; BIOLOGICAL THERAPY; CHICKENPOX; CLINICAL TRIAL; CONGENITAL HEART MALFORMATION; CONGENITAL MALFORMATION; CROHN DISEASE; DRUG BLOOD LEVEL; DRUG COMPETITION; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG PENETRATION; DRUG SAFETY; DRUG TRANSPORT; ENTERITIS; FEMALE FERTILITY; FEMALE SUBFERTILITY; FERTILIZATION IN VITRO; FETUS DEATH; FIRST TRIMESTER PREGNANCY; HUMAN; KIDNEY MALFORMATION; LIMB MALFORMATION; MEASLES; MUMPS; NEWBORN DISEASE; NEWBORN PERIOD; NONHUMAN; ORGANOGENESIS; PATIENT COUNSELING; PATIENT MONITORING; PNEUMOCOCCAL INFECTION; POLIOMYELITIS; PREGNANCY; PREGNANCY OUTCOME; PREMATURE LABOR; PRENATAL DRUG EXPOSURE; RHEUMATOID ARTHRITIS; ROTAVIRUS INFECTION; RUBELLA; SIDE EFFECT; SPONTANEOUS ABORTION; TERATOGENICITY; TH1 CELL; TH2 CELL; TRACHEOESOPHAGEAL FISTULA; TREATMENT DURATION; ULCERATIVE COLITIS; VACCINATION; VERTEBRA MALFORMATION;

EID: 78650074546     PISSN: 02774208     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Andres PG, Friedman LS. Epidemiology and the natural course of inflammatory bowel disease. Gastroenterol Clin North Am 1999;28:255-81, vii.
2. Hill JA, Polgar K, Anderson DJ. T-helper 1-type immunity to trophoblast in women with recurrent spontaneous abortion. JAMA 1995;273:1933-6.
3. Lin H, Mosmann TR, Guilbert L, Tuntipopipat S, Wegmann TG. Synthesis of T helper 2-type cytokines at the maternal-fetal interface. J Immunol 1993;151:4562-73.
4. Winger EE, Reed JL, Ashoush S, Ahuja S, El-Toukhy T, Taranissi M. Treatment with adalimumab (Humira) and intravenous immunoglobulin improves pregnancy rates in women undergoing IVF. Am J Reprod Immunol 2009;61:113-20.
5. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359:1541-9.
6. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462-76.
7. Simister NE. Placental transport of immunoglobulin G. Vaccine 2003;21:3365-9.
8. Vasiliauskas EA, Church JA, Silverman N, Barry M, Targan SR, Dubinsky MC. Case report: evidence for transplacental transfer of maternally administered infliximab to the newborn. Clin Gastroenterol Hepatol 2006;4:1255-8.
9. Mahadevan U TJ, Church, J et al. Infliximab levels in infants born to women with inflammatory bowel disease. Gastroenterol 2007;132:A-144.
10. Lichtenstein G, Cohen RD, Feagan BG, et al. Safety of Infliximab in Crohn's Disease: Data from the 5000-Patient TREAT Registry. Gastroenterology 2004;126:A54.
11. Katz JA, Antoni C, Keenan GF, Smith DE, Jacobs SJ, Lichtenstein GR. Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis. Am J Gastroenterol 2004;99:2385-92.
12. Mahadevan U, Kane S, Sandborn WJ, et al. Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn's disease. Aliment Pharmacol Ther 2005;21:733-8.
13. Schnitzler F FH, Ferrante M, Noman M, Van Assche G, Spitz B, Vermeire S, Rutgeerts P. Intentional treatmetn with infliximab during pregnancy in women with inflammatory bowel disease (Abstract). Gastroenterology 2007;132:Abstract 958.
14. Carter JD, Ladhani A, Ricca LR, Valeriano J, Vasey FB. A Safety Assessment of Tumor Necrosis Factor Antagonists During Preg- nancy: A Review of the Food and Drug Administration Database. J Rheumatol 2008.
15. Mahadevan U MC, Sandler R, et. al. A Multi-Center National Prospective study of pregnancy and neonatal outcomes in women with inflammatory bowel disease exposed to immunomodulators and biologic therapy. Gastroenterology 2009;136:Abstract #562.
16. Kane S, Ford J, Cohen R, Wagner C. Absence of Infliximab in Infants and Breast Milk From Nursing Mothers Receiving Therapy for Crohn's Disease Before and After Delivery. J Clin Gas- troenterol 2009;43:613-6.
17. Peltier M JD, Ford J., et al. Infliximab levels in breast-milk of a nursing Crohn's patient. American Journal of Gastroenterology 2001;96:P258.
18. Hanauer SB, Stromberg U. Oral Pentasa in the treatment of active Crohn's disease: A meta-analysis of double-blind, placebo-con- trolled trials. Clin Gastroenterol Hepatol 2004;2:379-88.
19. Coburn LA, Wise PE, Schwartz DA. The successful use of adalimumab to treat active Crohn's disease of an ileoanal pouch dur- ing pregnancy. Dig Dis Sci 2006;51:2045-7.
20. Mishkin DS, Van Deinse W, Becker JM, Farraye FA. Successful use of adalimumab (Humira) for Crohn's disease in pregnancy. Inflamm Bowel Dis 2006;12:827-8.
21. Vesga L, Terdiman JP, Mahadevan U. Adalimumab use in pregnancy. Gut 2005;54:890.
22. Chambers CD JD, Jones KL. Pregnancy Outcomes in Women Exposed to Adalimumab: The OTIS Autoimmune Diseases in Pregnancy Project. Personal communication July 13, 2007.
23. Lichtenstein GR, Thomsen OO, Schreiber S, et al. Continuous Therapy With Certolizumab Pegol Maintains Remission of Patients With Crohn's Disease for up to 18 Months. Clin Gas- troenterol Hepatol 2010.
24. Nesbitt A BD, Stephens S, Foulkes R. Placental Transfer and Accumulation in Milk of the Anti-TNF Antibody TN3 in Rats: Immunoglobulin G1 Versus PEGylated Fab' Am J Gastroenterol 2006:Abstract 119.
25. Mahadevan U SC, Abreu M. Certolizumab Use in Pregnancy: Low Levels Detected in Cord Blood. Gastroenterology 2009;136:Abstract 960.
26. Mahadevan U KS, Church J, Vasiliauskas E, Sandborn W, Dubinsky M. The Effect of Maternal Peripartum Infliximab Use on Neonatal Immune Response. Gastroenterology 2008;134: A-69 (abstract).
27. Kaine JL, Kivitz AJ, Birbara C, Luo AY. Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab. J Rheumatol 2007;34:272-9.
28. Melmed GY, Agarwal N, Frenck RW, et al. Immunosuppression impairs response to pneumococcal polysaccharide vaccination in patients with inflammatory bowel disease. Am J Gastroenterol 2010;105:148-54.
29. Sands BE, Cuffari C, Katz J, et al. Guidelines for immunizations in patients with inflammatory bowel disease. Inflamm Bowel Dis 2004;10:677-92.